Global Forum 2026
Thank you for an amazing Global Forum 2026!
It was a day filled with high-value networking and deep insights. We had the pleasure of hosting insightful panel discussions on The Insights Stage, covering shifting market trends, capital, and cross-border partnerships. Key highlights included exploring how European life science funding models need to evolve, navigating the massive commercial opportunities within women’s health, and debating how Big Pharma is proactively managing the late-2020s patent cliff to secure new assets.
Alongside these discussions, attendees had the enjoyment of 30+ company presentations on our Bubbles & Pitch Stage, showcasing laboratory innovations and disruptive technologies from the most promising up-and-coming biotechs.
Whether you want to rewatch your favorite moments or caught a session you missed, you can now find the recordings from the day down below!
Panel discussions & Keynotes
Keynote: Aaron Gu – What You Should Know About the Chinese Life Sciences Market – Highlights, Opportunities and Trends
Under BioStock Global Forum 2026 intog Aaron Gu,...
Panel: The fight for Assets: Winning the race to be the ”Partner of Choice”
I takt med att ett stort antal patentutgångar...
Text: et
Panel:Invented in Europe, owned by America
Panel: Unlocking the potential of women’s health: the next investment frontier
Trots historisk underfinansiering genomgår kvinnohälsa just nu en...
Panel:The Digital Health Paradox: Booming Developments, Broken Investment Models
Frågan om varför digital hälsa aldrig har känts...
Keynote: Strategic Blueprints for AI-Driven R&D: Navigating the Era of Pharmaceutical Superintelligence
Hur ser framtidens läkemedelsutveckling ut när generativ AI,...
Panel: Through the secret door and beyond
Under BioStock Global Forum 2026 intog en panel...
All recordings of Company Presentations
AcuCort | Global Forum 2026
CEO Jonas Jönmark presents AcuCort at Global Forum...
Aligned Bio | Global Forum 2026
CEO Kenneth Harlow presents Aligned Bio at Global...
Annexin Pharmaceuticals | Global Forum 2026
CEO Anders Haegerstrand presents Annexin Pharmaceuticals at Global...
Asgard Therapeutics | Global Forum 2026
CEO Cristiana Pires presents Asgard Therapeutics at Global...
Atrogi | Global Forum 2026
CEO Paul Little presents Atrogi at Global Forum...
Avenue Biosciences | Global Forum 2026
COO Katja Rosti presents Avenue Biosciences at Global...
BioInvent International | Global Forum 2026
CSO Björn Frendeus presents BioInvent International at Global...
BrainLit | Global Forum 2026
Founder Tord Wingren presents BrainLit at Global Forum...
CHOSA Oncology | Global Forum 2026
CCO Claus Frisenberg Petersen presents CHOSA Oncology at...
Circio | Global Forum 2026
CEO Erik Digman Wiklund presents Circio at Global...
Dicot | Global Forum 2026
CEO Elin Trampe presents Dicot at Global Forum...
Endoriz | Global Forum 2026
CEO Hanne Evenbratt presents Endoriz at Global Forum...
ExpreS2ion Biotech | Global Forum 2026
CEO Bent U. Frandsen presents ExpreS2ion Biotech at...
Hamlet BioPharma | Global Forum 2026
Chair Catharina Svanborg presents Hamlet BioPharma at Global...
Idun Biologics | Global Forum 2026
CTO Frederik Teilfeldt Hansen presents Idun Biologics at...
ImmuneBiotech | Global Forum 2026
CEO Shahram Lavasani presents ImmuneBiotech at Global Forum...
Initiator Pharma | Global Forum 2026
CEO Claus Elsborg Olesen presents Initiator Pharma at...
InnoCon Medical | Global Forum 2026
Bjarne Flou, Head of Commercial Strategy, presents InnoCon...
Kripthonite Therapeutics | Global Forum 2026
CEO Jan Stenvang presents Kripthonite Therapeutics at Global Forum...
Neogap Therapeutics | Global Forum 2026
CEO Samuel Svensson presents Neogap Therapeutics at Global...
OptiSense Care | Global Forum 2026
CEO Peter Rybäck presents OptiSense Care at Global...
Paindrainer | Global Forum 2026
CEO Erik Frick presents Paindrainer at Global Forum...
Xintela | Global Forum 2026
CEO Evy Lundgren-Åkerlund presents Xintela at Global Forum...
Zelluna | Global Forum 2026
CEO Namir Hassan presents ZELLUNA at Global Forum...
Synklino | Global Forum 2026
CEO Thomas Kledal presents Synklino at Global Forum 2026.
Tetraneuron | Global Forum 2026
Managing Director Mari Carmen Alvarez Abril presents Tetraneuron...
SynAct Pharma | Global Forum 2026
CBO Mads Bjerregaard presents SynAct Pharma at Global...
Simris Group | Global Forum 2026
Julian Read, Board of Directors, presents Simris Group...
Sprint Bioscience | Global Forum 2026
CEO Johan Emilsson presents Sprint Bioscience at Global...
Strike Pharma | Global Forum 2026
CEO Per Norlén presents Strike Pharma at Global...
Sigrid Therapeutics | Global Forum 2026
CEO Claus Kjærsgaard presents Sigrid Therapeutics at Global...
PharmNovo | Global Forum 2026
CEO Per von Mentzer presents PharmNovo at Global...
On stage
PRESENTING INNOVATORS
Panel Discussions 2026
Discover some of the topics coming to our Main Stage 2026. More cutting‑edge discussions are being added all the time.
The Fight for Assets: Winning the race to be the "Partner of Choice"
With the impending patent cliff approaching in the late 2020s, Big Pharma is under immense pressure to replenish pipelines. But high-quality assets are scarce, and the competition to acquire them is fierce. It is no longer enough for Pharma to simply sit back and evaluate; they must actively pitch their culture, speed, and scientific capabilities to win over the best innovators.
We debate what truly differentiates a winning bid in today’s market. Is it just about the highest valuation, or are factors like agility, therapeutic fit, and creative deal structures becoming the deciding factors for biotechs choosing their future partner?
Invented in Europe, owned by America
Europe produces world-class science and creates innovative start-ups at a record pace. Yet, when companies reach the critical expansion phase, the funding trail often leads across the Atlantic. As late-stage rounds grow larger and more infrequent, European VCs are struggling to compete with the deep pockets of US investors.
We debate the structural changes needed to keep our most promising scale-ups on European soil. Do we need mega-funds, government intervention, or a fundamental shift in risk appetite? This panel explores if European VC has the muscle to support companies all the way to commercialization, or if we are destined to remain a seed-stage market.
The Digital Health Paradox: Booming developments, Broken Investment Models
In this panel, leading digital health investors dissect the paradox: why has the sector never looked more necessary, yet never been harder to fund? We explore whether current business models are fundamentally flawed, if AI-powered products can restore investor confidence, and what it will take for Europe and the Nordics to build digital health companies that scale beyond pilot projects and fragmented health systems.
Introducing Our Two-Stage Format
We are thrilled to introduce a dual-stage experience designed to bridge the gap between emerging breakthroughs and industry leadership.
The Bubbles & Pitch Stage: Your front-row seat to the future. Discover the latest laboratory innovations and disruptive technologies from the most promising up-and-comers in the field, while sipping some sparkly bubbles. 🥂
The Insights Stage: Industry experts, investors and big pharma. Join us for high-level keynotes and panel discussions featuring established global leaders tackling market trends, capital, and cross-border partnerships.
Whether you are looking for the next big investment on the Bubbles & Pitch stage or strategic insights on the Main Stage, this year’s curated layout ensures you get the best of both worlds without the overwhelm.
Global Forum 2025
Gold Partner
Silver partners
Bronze Partner
About our event partners
DNB Carnegie | Back Bay
DNB Carnegie | Back Bay is a unique integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies.
We combine scientific and strategic expertise with financing origination and execution to support healthcare companies of all sizes through each stage of growth—from chemistry to commercialization. Learn more and subscribe for our market updates: www.bblsa.com/dnb-carnegie-back-bay-partnership
Nasdaq
With more than 90 pct. of all US biotech, pharma & life science companies listed on Nasdaq, we know how to match savvy investors with trail-blazing inventors.
We are here to support your ideas and the next steps to a public offering that keeps you in control while raising capital to ignite your ambition. By the way, if you want to keep your ambition closer to home, Nasdaq in the Nordic is the leading hub for listed biotech and health care companies in Europe, with strong support from investors and innovation communities across the region.
How to join the Nasdaq family? – Read more here.
